All Trials

A Phase I Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable metastatic colorectal adenocarcinoma who have progressed after at least two prior lines of therapy and have ECOG 0-1 are eligible to receive investigational JNJ-89402638 (mechanism of action not disclosed); the study uses dose escalation and expansion to assess safety and determine the recommended phase 2 dose.

ClinicalTrials.gov ID: NCT06663319

A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Eligible patients have advanced or metastatic colorectal or gastroesophageal adenocarcinoma with prior treatment failure, and will receive oral trifluridine/tipiracil plus talazoparib, a PARP inhibitor targeting DNA repair, to evaluate safety and dosing. Certain biomarker-defined cohorts are also included.

ClinicalTrials.gov ID: NCT04511039

A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors—primarily colorectal cancer but also including HCC, TNBC, NSCLC, ovarian cancer, melanoma, cholangiocarcinoma, and synovial sarcoma—who have progressed on or are ineligible for standard treatments. Patients receive intravenous ST316, a β-catenin/BCL9 interaction inhibitor targeting aberrant WNT/β-catenin signaling, as monotherapy or in combination with standard regimens in CRC.

ClinicalTrials.gov ID: NCT05848739

A Phase 1a/1b, First-in-human, Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study is enrolling adults with advanced, relapsed, or refractory adenoid cystic carcinoma or colorectal carcinoma who have exhausted standard therapies, to receive the oral MYB mRNA-targeting inhibitor RGT-61159. RGT-61159 degrades MYB mRNA via altered splicing and nonsense-mediated decay, aiming to reduce MYB protein in these cancers.

ClinicalTrials.gov ID: NCT06462183

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Eligible patients are adults with metastatic or unresectable solid tumors harboring a G12V mutation in KRAS, NRAS, or HRAS who are HLA-A*11:01 positive and have progressed on or declined standard therapies. Treatment involves lymphodepleting chemotherapy followed by infusion of autologous peripheral blood lymphocytes genetically modified to express a murine T-cell receptor targeting the G12V RAS mutation, along with high-dose aldesleukin.

ClinicalTrials.gov ID: NCT03190941

A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced cancers and predominant hepatic metastases, including a cohort with metastatic colorectal cancer and another with liver metastases harboring PI3K pathway activation, testing the addition of the investigational NovoTTF-100L(P) system (tumor treating electric fields targeting mitosis) to standard chemotherapy and bevacizumab. Treatments include FOLFOX6 plus bevacizumab for colorectal cancer, or pegylated liposomal doxorubicin, temsirolimus (an mTOR inhibitor), and bevacizumab for PI3K pathway-activated cases.

ClinicalTrials.gov ID: NCT03203525

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with HLA-A*11:01-positive, metastatic or unresectable solid tumors harboring a G12D mutation in KRAS, NRAS, or HRAS who have progressed on standard therapy, and treats them with lymphodepleting chemotherapy followed by autologous T-cells engineered with a murine T-cell receptor targeting the G12D RAS mutation, plus high-dose IL-2. The investigational therapy specifically redirects T-cells to recognize and kill G12D-mutant RAS cancer cells presented by HLA-A*11:01.

ClinicalTrials.gov ID: NCT03745326

A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, relapsed or refractory solid tumors known to express ADAM9—including NSCLC adenocarcinoma, cholangiocarcinoma, colorectal, and pancreatic cancers—to receive MGC028, an investigational antibody-drug conjugate targeting ADAM9 with a topoisomerase I inhibitor payload. Patients must have measurable disease and accessible tissue for testing; prior treatment limits apply in expansion cohorts.

ClinicalTrials.gov ID: NCT06723236

A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, FAP-positive solid tumors who have progressed on or lack standard therapy, using [203Pb]Pb-PSV359 SPECT imaging to confirm FAP expression and [212Pb]Pb-PSV359, a FAP-targeted alpha-emitting peptide-radiopharmaceutical, for systemic therapy.

ClinicalTrials.gov ID: NCT06710756

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced solid tumors that are mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H), including those with previously treated colorectal or endometrial cancer, to receive the investigational oral Werner DNA helicase (WRN) inhibitor GSK4418959—alone or combined with a PD-1 inhibitor—to target DNA repair vulnerabilities in these tumors. Patients must have exhausted standard treatment options and have good performance status.

ClinicalTrials.gov ID: NCT06710847